PCI Biotech Holding ASA (DE:4QG) has released an update.
PCI Biotech has announced positive interim results for the first half of 2024, highlighting the potential of its photochemical-based technology (PCL) in the manufacturing of viral vectors, a key component in gene therapy. The company has transitioned to mini benchtop bioreactor testing with a service provider to further scale-up the technology, showing initial compatibility with standard manufacturing processes. With a cash position supporting operations into the second half of 2025, PCI Biotech aims to demonstrate the commercial viability of its technology platform.
For further insights into DE:4QG stock, check out TipRanks’ Stock Analysis page.
